| Tbio | Netrin receptor UNC5C |
Receptor for netrin required for axon guidance. Mediates axon repulsion of neuronal growth cones in the developing nervous system upon ligand binding. Axon repulsion in growth cones may be caused by its association with DCC that may trigger signaling for repulsion. Also involved in corticospinal tract axon guidances independently of DCC. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand.
This gene product belongs to the UNC-5 family of netrin receptors. Netrins are secreted proteins that direct axon extension and cell migration during neural development. They are bifunctional proteins that act as attractants for some cell types and as repellents for others, and these opposite actions are thought to be mediated by two classes of receptors. The UNC-5 family of receptors mediate the repellent response to netrin; they are transmembrane proteins containing 2 immunoglobulin (Ig)-like domains and 2 type I thrombospondin motifs in the extracellular region. [provided by RefSeq, Jul 2008]
This gene product belongs to the UNC-5 family of netrin receptors. Netrins are secreted proteins that direct axon extension and cell migration during neural development. They are bifunctional proteins that act as attractants for some cell types and as repellents for others, and these opposite actions are thought to be mediated by two classes of receptors. The UNC-5 family of receptors mediate the repellent response to netrin; they are transmembrane proteins containing 2 immunoglobulin (Ig)-like domains and 2 type I thrombospondin motifs in the extracellular region. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | 124 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Renal Cell Carcinoma | 214 |
| Schizophrenia | 1160 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 8.4e-16 |
| glioblastoma | 5792 | 9.2e-07 |
| Breast cancer | 3578 | 7.9e-06 |
| adult high grade glioma | 3801 | 7.1e-05 |
| group 3 medulloblastoma | 4104 | 2.8e-04 |
| medulloblastoma, large-cell | 6241 | 1.0e-03 |
| adrenocortical carcinoma | 1428 | 2.8e-03 |
| atypical teratoid / rhabdoid tumor | 5112 | 3.3e-03 |
| subependymal giant cell astrocytoma | 2287 | 3.4e-03 |
| astrocytic glioma | 2597 | 6.5e-03 |
| ependymoma | 4679 | 1.0e-02 |
| oligodendroglioma | 2850 | 2.7e-02 |
| active ulcerative colitis | 764 | 3.0e-02 |
| primitive neuroectodermal tumor | 3035 | 3.5e-02 |
| osteosarcoma | 7950 | 4.1e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Alzheimer's disease | 658 | 0.0 | 2.0 |
| Rheumatoid arthritis | 1191 | 0.0 | 1.1 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Colorectal cancer | 25 | 3.488 | 1.7 |
| Disease | log2 FC | p |
|---|---|---|
| active ulcerative colitis | -1.041 | 3.0e-02 |
| adrenocortical carcinoma | -1.772 | 2.8e-03 |
| adult high grade glioma | -2.100 | 7.1e-05 |
| astrocytic glioma | -1.700 | 6.5e-03 |
| atypical teratoid / rhabdoid tumor | -1.700 | 3.3e-03 |
| Breast cancer | -1.200 | 7.9e-06 |
| ependymoma | -2.000 | 1.0e-02 |
| glioblastoma | -2.000 | 9.2e-07 |
| group 3 medulloblastoma | -1.900 | 2.8e-04 |
| medulloblastoma, large-cell | -1.500 | 1.0e-03 |
| oligodendroglioma | -1.400 | 2.7e-02 |
| osteosarcoma | -1.265 | 4.1e-02 |
| primitive neuroectodermal tumor | -1.300 | 3.5e-02 |
| psoriasis | -1.100 | 8.4e-16 |
| subependymal giant cell astrocytoma | -2.342 | 3.4e-03 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA | ||
| Inparanoid OMA | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA | ||
| Inparanoid OMA | ||
| Inparanoid OMA | ||
| Inparanoid OMA | ||
| Inparanoid OMA | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG |
MRKGLRATAARCGLGLGYLLQMLVLPALALLSASGTGSAAQDDDFFHELPETFPSDPPEPLPHFLIEPEE 1 - 70 AYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDHIVDERVDETSGLIVREVSIEISRQQVEELFGPEDY 71 - 140 WCQCVAWSSAGTTKSRKAYVRIAYLRKTFEQEPLGKEVSLEQEVLLQCRPPEGIPVAEVEWLKNEDIIDP 141 - 210 VEDRNFYITIDHNLIIKQARLSDTANYTCVAKNIVAKRKSTTATVIVYVNGGWSTWTEWSVCNSRCGRGY 211 - 280 QKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLCPVDGRWTPWSKWSTCGTECTHWRRRECTAPAPKNGGK 281 - 350 DCDGLVLQSKNCTDGLCMQTAPDSDDVALYVGIVIAVIVCLAISVVVALFVYRKNHRDFESDIIDSSALN 351 - 420 GGFQPVNIKAARQDLLAVPPDLTSAAAMYRGPVYALHDVSDKIPMTNSPILDPLPNLKIKVYNTSGAVTP 421 - 490 QDDLSEFTSKLSPQMTQSLLENEALSLKNQSLARQTDPSCTAFGSFNSLGGHLIVPNSGVSLLIPAGAIP 491 - 560 QGRVYEMYVTVHRKETMRPPMDDSQTLLTPVVSCGPPGALLTRPVVLTMHHCADPNTEDWKILLKNQAAQ 561 - 630 GQWEDVVVVGEENFTTPCYIQLDAEACHILTENLSTYALVGHSTTKAAAKRLKLAIFGPLCCSSLEYSIR 631 - 700 VYCLDDTQDALKEILHLERQMGGQLLEEPKALHFKGSTHNLRLSIHDIAHSLWKSKLLAKYQEIPFYHVW 701 - 770 SGSQRNLHCTFTLERFSLNTVELVCKLCVRQVEGEGQIFQLNCTVSEEPTGIDLPLLDPANTITTVTGPS 771 - 840 AFSIPLPIRQKLCSSLDAPQTRGHDWRMLAHKLNLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLA 841 - 910 AVLEEMGRHETVVSLAAEGQY 911 - 931 //
